Tevogen Bio Holdings Files 8-K

TL;DR

Tevogen Bio Holdings filed an 8-K on Jan 28, 2025, updating on stock, warrants, and financials.

AI Summary

Tevogen Bio Holdings Inc. filed an 8-K on January 28, 2025, reporting on various events. The filing includes information related to its common stock and warrants, as well as financial statements and exhibits. The company, formerly known as Semper Paratus Acquisition Corp., changed its name on May 5, 2021.

Why It Matters

This 8-K filing provides an update on Tevogen Bio Holdings' corporate structure and financial reporting, which is important for investors to understand the company's current status.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new risks.

Key Players & Entities

• Tevogen Bio Holdings Inc. (company) — Registrant
• Semper Paratus Acquisition Corp. (company) — Former company name
• January 28, 2025 (date) — Date of earliest event reported
• May 5, 2021 (date) — Date of name change

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share TVGN The Nasdaq Stock Mar
• $11.50 — sable for one share of Common Stock for $11.50 per share TVGNW The Nasdaq Stock Ma
• $2,000,000 — nounced that it had received a grant of $2,000,000 from KRHP LLC, a New Jersey limited lia

Filing Documents

• form8-k.htm (8-K) — 42KB
• ex99-1.htm (EX-99.1) — 17KB
• ex99-1_001.jpg (GRAPHIC) — 2KB
• 0001493152-25-004002.txt ( ) — 288KB
• tvgn-20250128.xsd (EX-101.SCH) — 4KB
• tvgn-20250128_def.xml (EX-101.DEF) — 29KB
• tvgn-20250128_lab.xml (EX-101.LAB) — 36KB
• tvgn-20250128_pre.xml (EX-101.PRE) — 26KB
• form8-k_htm.xml (XML) — 6KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2025 Tevogen Bio Holdings Inc. (Exact name of registrant as specified in its charter) Delaware 001-41002 98-1597194 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 15 Independence Boulevard , Suite #410 Warren , New Jersey 07059 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (877) 838-6436 Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.0001 per share TVGN The Nasdaq Stock Market LLC Warrants, each exercisable for one share of Common Stock for $11.50 per share TVGNW The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 7.01 Regulation FD Disclosure. On January 28, 2025, Tevogen Bio Holdings Inc. (the "Company") issued a press release announcing that it had received the grant described in Item 8.01 below. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. Item 8.01 Other Events. On January 28, 2025, the Company announced that it had received a grant of $2,000,000 from KRHP LLC, a New Jersey limited liability company, to further the Company's development of off-the-shelf, genetically unmodified precision T cell therapeutics to treat infectious diseases and cancers. KRHP is affiliated with the spouse of Dr. Manmohan Patel, an existing investor in the Company and beneficial owner of more than 5% of the Company's common stock, par value $0.0001 per share. Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit Description 99.1 Press Release, dated January 28, 2025 104.1 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Tevogen Bio Holdings Inc. Date: January 28, 2025 By: /s/ Ryan Saadi Name: Ryan Saadi Title: Chief Executive Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR